Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Tue, Mar 18, 2025
[Archive]
Volume 15, Issue 1 (Winter 2024)
Caspian J Intern Med 2024, 15(1): 28-37 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Wikananda I M F, Nurcahya I G N M, Wijaya P G P M, Widiana I G R, Sindhughosa D A. Effects of Nebivolol therapy on hemodynamic parameters and lipid profile compared to other beta blockers in patients with essential hypertension: a systematic review and meta-analysis. Caspian J Intern Med 2024; 15 (1) :28-37
URL: http://caspjim.com/article-1-3845-en.html
URL: http://caspjim.com/article-1-3845-en.html
I Made Fermi Wikananda * 
, I Gusti Ngurah Metta Nurcahya , Putu Gede Pradipta Mahardika Wijaya , I Gde Raka Widiana , Dwijo Anargha Sindhughosa
, I Gusti Ngurah Metta Nurcahya , Putu Gede Pradipta Mahardika Wijaya , I Gde Raka Widiana , Dwijo Anargha Sindhughosa
Faculty of Medicine, Udayana University, Denpasar, Indonesia , imadefermiwikananda@gmail.com
Abstract: (1615 Views)
Background: Besides being commonly used to treat high blood pressure, beta blockers are a family of drugs that are primarily used to regulate irregular cardiac rhythms. Nebivolol is a third generation of beta blockers, which is highly cardioselective, about three times as selective as bisoprolol. In this study, we aimed to evaluate Nebivolol's effectiveness and safety in comparison to other beta blockers.
Methods: We searched the online databases PubMed, ScienceDirect, and Cochrane Library for relevant RCTs evaluating Nebivolol's effect on hypertension management. Relative risk (WRR) and weighted mean difference (WMD), with a 95% confidence interval (CI) were utilized to quantify the impact of nebivolol medication in the treatment of hypertension using a random effects model.
Results: Twelve RCTs are included in the study, the patient numbers in every attempt ranged from 42-273 and 1456 patients in all were included in this review. Nebivolol does not significantly reduce SBP, DBP and HR compared to other beta blockers (WMD −0.57 mmHg, 95% CI [−1.55;0.42 mmHg] p=0.12 ; WMD −0.27 mmHg, 95% CI [−1.36;0.82 mmHg] p=0.63 ; WMD 0.10 BPM, 95% CI [−4.11;1.31 BPM] p=0.96, respectively). Patients treated with Nebivolol has significantly lower LDL-C (WMD -8.88 mg/dL, 95% CI [−15.28; -2.48 mg/dL] p=0.007) and significantly higher HDL-C (WMD 2.30 mg/dL, 95% CI [0.75; 3.84 mg/dL] p=0.004.
Conclusions: According to this study's findings, nebivolol is well tolerated and decreases LDL-C. And higher HDL-C than other beta blocker agents. This review does not recommend nebivolol as first-line treatment in hypertension as Nebivolol does not significantly reduce blood pressure and HR of patients.
Methods: We searched the online databases PubMed, ScienceDirect, and Cochrane Library for relevant RCTs evaluating Nebivolol's effect on hypertension management. Relative risk (WRR) and weighted mean difference (WMD), with a 95% confidence interval (CI) were utilized to quantify the impact of nebivolol medication in the treatment of hypertension using a random effects model.
Results: Twelve RCTs are included in the study, the patient numbers in every attempt ranged from 42-273 and 1456 patients in all were included in this review. Nebivolol does not significantly reduce SBP, DBP and HR compared to other beta blockers (WMD −0.57 mmHg, 95% CI [−1.55;0.42 mmHg] p=0.12 ; WMD −0.27 mmHg, 95% CI [−1.36;0.82 mmHg] p=0.63 ; WMD 0.10 BPM, 95% CI [−4.11;1.31 BPM] p=0.96, respectively). Patients treated with Nebivolol has significantly lower LDL-C (WMD -8.88 mg/dL, 95% CI [−15.28; -2.48 mg/dL] p=0.007) and significantly higher HDL-C (WMD 2.30 mg/dL, 95% CI [0.75; 3.84 mg/dL] p=0.004.
Conclusions: According to this study's findings, nebivolol is well tolerated and decreases LDL-C. And higher HDL-C than other beta blocker agents. This review does not recommend nebivolol as first-line treatment in hypertension as Nebivolol does not significantly reduce blood pressure and HR of patients.
Type of Study: Original Article |
Subject:
Internal
Received: 2023/02/3 | Accepted: 2024/01/9 | Published: 2024/01/9
Received: 2023/02/3 | Accepted: 2024/01/9 | Published: 2024/01/9
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
